Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954

Human Gene Therapy

Volumn 16, Issue 12, 2005, Pages 1473-1483

  Lukashev, Alexander N ^a   Fuerer, Christophe ^a   Chen, Ming Jen ^b   Searle, Peter ^c   Iggo, Richard ^a,d  

^a SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; E1A PROTEIN; E1B PROTEIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NITROREDUCTASE; ONCOLYTIC VIRUS; PRODRUG; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; VIRUS PROTEIN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG SELECTIVITY; ESCHERICHIA COLI; GENE DELETION; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LUNG FIBROBLAST; MALE; MOUSE; NFSB GENE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AZIRIDINES; CELL LINE; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ESCHERICHIA COLI PROTEINS; FIBROBLASTS; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; NITROREDUCTASES; ONCOLYTIC VIRUSES; PRODRUGS; SIROLIMUS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; ESCHERICHIA COLI; MAMMALIA; MUS MUSCULUS;

EID: 29244455327     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1473     Document Type: Article

References (44)

1. ANLEZARK, G.M., MELTON, R.G., SHERWOOD, R.F., COLES, B., FRIEDLOS, F., and KNOX, R.J. (1992). The bioactivation of 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coli: A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44, 2289-2295.
2. BILSLAND, A.E., ANDERSON, C.J., FLETCHER-MONAGHAN, A.J., MCGREGOR, F., EVANS, T.R., GANLY, I., KNOX, R.J., PLUMB, J.A., and KEITH, W.N. (2003). Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22, 370-380.
3. BRUNORI, M., MALERBA, M., KASHIWAZAKI, H., and IGGO, R. (2001). Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol. 75, 2857-2865.
4. CHEN, M.J., GREEN, N.K., REYNOLDS, G.M., FLAVELL, J.R., MAUTNER, V., KERR, D.J., YOUNG, L.S., and SEARLE, P.F. (2004). Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther. 11, 1126-1136.
5. DENBY, L., WORK, L.M., GRAHAM, D., HSU, C., VON SEGGERN, D.J., NICKLIN, S.A., and BAKER, A.H. (2004). Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 15, 1054-1064.
6. DJEHA, A.H., HULME, A., DEXTER, M.T., MOUNTAIN, A., YOUNG, L.S., SEARLE, P.F., KERR, D.J., and WRIGHTON, C.J. (2000). Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 7, 721-731.
7. DJEHA, A.H., THOMSON, T.A., LEUNG, H., SEARLE, P.F., YOUNG, L.S., KERR, D.J., HARRIS, P.A., MOUNTAIN, A., and WRIGHTON, C.J. (2001). Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. Mol. Ther. 3, 233-240.
8. DORONIN, K., TOTH, K., KUPPUSWAMY, M., KRAJCSI, P., TOLLEFSON, A.E., and WOLD, W.S. (2003). Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378-387.
9. FALLAUX, F.J., KRANENBURG, O., CRAMER, S.J., HOUWELING, A., VAN ORMONDT, H., HOEBEN, R.C., and VAN DER EB, A.J. (1996). Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7, 215-222.
10. FREYTAG, S.O., ROGULSKI, K.R., PAIELLI, D.L., GILBERT, J.D., and KIM, J.H. (1998). A novel three-pronged approach to kill cancer cells selectively. Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323-1333.
11. FUERER, C., and IGGO, R. (2002). Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther. 9, 270-281.
12. FUERER, C., and IGGO, R. (2004). 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther. 11, 142-151.
13. GAGNEBIN, J., BRUNORI, M., OTTER, M., JUILLERAT-JEANNERET, L., MONNIER, P., and IGGO, R. (1999). A photosensitising adenovirus for photodynamic therapy. Gene Ther. 6, 1742-1750.
14. GREEN, N.K., HERBERT, C.W., HALE, S.J., HALE, A.B., MAUTNER, V., HARKINS, R., HERMISTON, T., ULBRICH, K., FISHER, K.D., and SEYMOUR, L.W. (2004). Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11, 1256-1263.
15. GROVE, J.I., LOVERING, A.L., GUISE, C., RACE, P.R., WRIGHTON, C.J., WHITE, S.A., HYDE, E.I., and SEARLE, P.F. (2003). Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res. 63, 5532-5537.
16. HAWKINS, L.K., and HERMISTON, T. (2001a). Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region. Gene Ther. 8, 1142-1148.
17. HAWKINS, L.K., and HERMISTON, T.W. (2001b). Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther. 8, 1132-1141.
18. HAWKINS, L.K., JOHNSON, L., BAUZON, M., NYE, J.A., CASTRO, D., KITZES, G.A., YOUNG, M.D., HOLT, J.K., TROWN, P., and HERMISTON, T.W. (2001). Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7 K/gp19 K region. Gene Ther. 8, 1123-1131.
19. HAWKINS, L.K., LEMOINE, N.R., and KIRN, D. (2002). Oncolytic biotherapy: A novel therapeutic platform. Lancet Oncol. 3, 17-26.
20. HOMICSKO, K., LUKASHEV, A., and IGGO, R. (2005). RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res. 65, 6882-6890.
21. KAGAWA, S., HE, C., GU, J., KOCH, P., RHA, S.J., ROTH, J.A., CURLEY, S.A., STEPHENS, L.C., and FANG, B. (2001). Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 61, 3330-3338.
22. KURIYAMA, N., KURIYAMA, H., JULIN, C.M., LAMBORN, K.R., and ISRAEL, M.A. (2001). Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res. 61, 1805-1809.
23. LATHAM, J.P., SEARLE, P.F., MAUTNER, V., and JAMES, N.D. (2000). Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res. 60, 334-341.
24. LIPINSKI, K.S., DJEHA, A.H., ISMAIL, T., MOUNTAIN, A., YOUNG, L.S., and WRIGHTON, C.J. (2001). High-level, β-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol. Ther. 4, 365-371.
25. LIPINSKI, K.S., DJEHA, H.A., GAWN, J., CLIFFE, S., MAITLAND, N.J., PALMER, D.H., MOUNTAIN, A., IRVINE, A.S., and WRIGHTON, C.J. (2004). Optimization of a synthetic β-catenin-dependent promoter for tumor-specific cancer gene therapy. Mol. Ther. 10, 150-161.
26. MARR, R.A., HITT, M., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1998). Tumour therapy in mice using adenovirus vectors expressing human TNFα. Int. J. Oncol. 12, 509-515.
27. MIZUGUCHI, H., and HAYAKAWA, T. (2004). Targeted adenovirus vectors. Hum. Gene Ther. 15, 1034-1044.
28. MIZUGUCHI, H., XU, Z., ISHII-WATABE, A., UCHIDA, E., and HAYAKAWA, T. (2000). IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol. Ther. 1, 376-382.
29. O'SHEA, C.C., JOHNSON, L., BAGUS, B., CHOI, S., NICHOLAS, C., SHEN, A., BOYLE, L., PANDEY, K., SORIA, C., KUNICH, J., SHEN, Y., HABETS, G., GINZINGER, D., and MCCORMICK, F. (2004). Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623.
30. PALMER, D.H., MAUTNER, V., MIRZA, D., OLIFF, S., GERRITSEN, W., VAN DER SIJP, J.R., HUBSCHER, S., REYNOLDS, G., BONNEY, S., RAJARATNAM, R., HULL, D., HORNE, M., ELLIS, J., MOUNTAIN, A., HILL, S., HARRIS, P.A., SEARLE, P.F., YOUNG, L.S., JAMES, N.D., and KERR, D.J. (2004). Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 22, 1546-1552.
31. RADTKE, F., and CLEVERS, H. (2005). Self-renewal and cancer of the gut: Two sides of a coin. Science 307, 1904-1909.
32. REICH, N.C., SARNOW, P., DUPREY, E., and LEVINE, A.J. (1983). Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 128, 480-484.
33. REID, T., WARREN, R., and KIRN, D. (2002). Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther. 9, 979-986.
34. ROGULSKI, K.R., WING, M.S., PAIELLI, D.L., GILBERT, J.D., KIM, J.H., and FREYTAG, S.O. (2000). Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. 11, 67-76.
35. SAUTHOFF, H., PIPIYA, T., HEITNER, S., CHEN, S., NORMAN, R.G., ROM, W.N., and HAY, J.G. (2002). Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum. Gene Ther. 13, 1859-1871.
36. SCHIEDNER, G., BLOCH, W., HERTEL, S., JOHNSTON, M., MOLOJAVYI, A., DRIES, V., VARGA, G., VAN ROOIJEN, N., and KOCHANEK, S. (2003). A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum. Gene Ther. 14, 1631-1641.
37. SEARLE, P.F., CHEN, M.J., HU, L., RACE, P.R., LOVERING, A.L., GROVE, J.I., GUISE, C., JABERIPOUR, M., JAMES, N.D., MAUTNER, V., YOUNG, L.S., KERR, D.J., MOUNTAIN, A., WHITE, S.A., and HYDE, E.I. (2004). Nitroreductase: A prodrug-activating enzyme for cancer gene therapy. Clin. Exp. Pharmacol. Physiol. 31, 811-816.
38. STUBDAL, H., PERIN, N., LEMMON, M., HOLMAN, P., BAUZON, M., POTTER, P.M., DANKS, M.K., FATTAEY, A., DUBENSKY, T., and JOHNSON, L. (2003). A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res. 63, 6900-6908.
39. SUZUKI, K., ALEMANY, R., YAMAMOTO, M., and CURIEL, D.T. (2002). The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res. 8, 3348-3359.
40. TAO, N., GAO, G.P., PARR, M., JOHNSTON, J., BARADET, T., WILSON, J.M., BARSOUM, J., and FAWELL, S.E. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3, 28-35.
41. VOLORIO, C. (2001). Construction et caractérisation d'adénovirus réplicatifs ciblant les cancers du colon. Travail de Certificat. University of Lausanne, Lausanne, Switzerland.
42. WEEDON, S.J., GREEN, N.K., MCNEISH, I.A., GILLIGAN, M.G., MAUTNER, V., WRIGHTON, C.J., MOUNTAIN, A., YOUNG, L.S., KERR, D.J., and SEARLE, P.F. (2000). Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int. J. Cancer 86, 848-854.
43. WILDNER, O., BLAESE, R.M., and MORRIS, J.C. (1999). Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 59, 410-413.
44. WINKLER, F., KOZIN, S.V., TONG, R.T., CHAE, S.S., BOOTH, M.F., GARKAVTSEV, I., XU, L., HICKLIN, D.J., FUKUMURA, D., DI TOMASO, E., MUNN, L.L., and JAIN, R.K. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563.